Shire sales and marketing update

Shire launched Natpara in the U.S. as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. The wholesale acquisition cost (WAC) of the recombinant human parathyroid hormone 1-84 (PTH) is $7,916.67 per 28-day package. Shire gained the Orphan drug this year in its $5.2 billion acquisition of NPS Pharmaceuticals Inc. (see BioCentury, March 2). ...